Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on August 9, 2022. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with listing standards. Note: The input metadata references "Insight Molecular Diagnostics Inc.," but the filing text explicitly identifies the registrant as Oncocyte Corporation.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point provided is the stock price performance triggering the regulatory notice:
- Stock Price: The minimum closing bid price was less than $1.00 for the previous 30 consecutive business days.
- Compliance Threshold: Nasdaq Listing Rule 5450(a)(1) requires a minimum closing bid price of $1.00.
Material Changes
The material change reported is the receipt of a formal notice from Nasdaq indicating the company no longer meets the minimum bid price requirement for continued listing. This status change places the company in a compliance grace period rather than an immediate delisting.
Guidance, Outlook, and Risks
Compliance Timeline: The company has a 180-calendar day grace period to regain compliance. To satisfy the standard, the stock must maintain a minimum closing bid price of at least $1.00 per share for 10 consecutive business days within this period.
Management Action: Management is monitoring the closing bid price and will consider available options to achieve compliance.
Risks and Contingencies: The filing includes a cautionary note regarding forward-looking statements. Risks include the potential for actual results to differ materially from expectations, which could adversely affect operations and stock price. The company explicitly states it undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the current trading price of OCX to assess proximity to the $1.00 compliance threshold.
- Monitor the company's 10-Q filing for the quarter ended June 30, 2022, for detailed financial risks referenced in this notice.
- Track any future announcements regarding reverse stock splits or other capital actions intended to restore the bid price.
- Confirm the exact date the 180-day grace period expires to understand the deadline for compliance.